Biopharma’s “big risk, big reward” strategy in psychiatric medicine

But the risk is just as immense. Biological pathways are complex, the failure rate of clinical trials is notoriously high, and the cost of bringing a single drug to market can exceed $2 billion.

So why are venture capitalists and pharmaceutical giants suddenly willing to take the gamble? The answer lies at the intersection of scientific progress and market needs. The patents on many old blockbuster antidepressants have expired, opening the door to generics and eroding profits. At the same time, our understanding of neuroscience has advanced to the point where these targeted bets are no longer projects made in the dark but risks calculated based on decades of research.

A prime example of this new calculus is the Food and Drug Administration’s recent approval of Karuna Therapeutics’ Cobenfy, a muscarinic agonist for schizophrenia. The drug represents the first new pharmacological approach to the disease’s symptoms in decades. The journey carried many risks, but its approval triggered a multibillion-dollar acquisition by Bristol Myers Squibb, a clear signal to the market that a successful bet in this area can generate astronomical returns.

However, the disappointing results from the Cobenfy phase 3 trials are a stark reminder that even approved candidates carry post-market risk, impacting long-term valuation. Cerevel Therapeutics is also emerging with a new novel drug, Emraclidine, targeting the muscarinic M4 receptor agonist, which is now entering late-stage trials.

This new era of high-risk, high-reward development is further shaped by a second powerful force: evolving FDA policy. The agency is no longer just a gatekeeper; he is an active architect of modern clinical trials. Recent FDA guidance fundamentally changes the cost, timing and strategic planning of drug development.

Specifically, requiring greater diversity in clinical trial populations is a long-overdue step toward health equity, but it introduces significant operational and financial complexity. Despite recent administrative actions, the FDA still requires a diversity action plan for clinical trials. Recruiting a patient population that accurately reflects the real world is more expensive and time-consuming than recruiting a homogeneous group. Companies must now invest heavily in community outreach, build trust with underrepresented groups and develop new logistics frameworks. For investors, this means longer time to yield and higher upfront R&D costs.

At the same time, the FDA’s growing acceptance of real-world evidence collected from sources outside of traditional clinical trials, such as electronic health records and wearable devices, is creating new opportunities. Companies that can effectively leverage real-world evidence can potentially streamline post-market surveillance and better demonstrate a drug’s long-term value to payers. This creates a new ecosystem of data analytics companies and technology partnerships, adding another layer of strategic complexity to the sector.

The long-term economic impact of these converging trends will be transformative. The “blockbuster or bust” model will intensify, leading to greater market volatility for biotech stocks. We can expect a wave of mergers and acquisitions as large pharmaceutical companies, reluctant to take the early-stage risk themselves, seek to acquire smaller biotech companies that have successfully moved a drug through mid-stage trials.

For insurers and health systems, the potential arrival of these new, costly and highly effective therapies will in turn pose a significant challenge. They will need to develop new models to assess value and manage costs, balancing the high price of innovation with the potential for long-term savings from reduced hospitalizations and improved patient productivity.

The era of safe values ​​in psychiatric medicine is over. The new landscape is defined by high-risk science, complex regulatory requirements and the potential for market-defining rewards. This is a more challenging and uncertain environment, but for the millions of patients waiting for a real breakthrough, it is also the most hopeful environment in a generation.

Khutaija Noor is a clinical researcher with advanced training at Harvard who leads clinical trials for Amicis Clinical Trials studies and previously contributed to clinical research at the University of Washington. She is also a corresponding member of the scientific committee of the American Psychiatric Association.